• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAB 0.00% 0.8¢

PATRYS LIMITED

Patrys Limited is an Australia-based company, which is focused on the development of its... Patrys Limited is an Australia-based company, which is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. It has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
PAB 13:10 11 4.2K
13:10 Last post  gassed Comments Created with Sketch.  11  Views Created with Sketch.  4.2K 
PAB 17/05/24 27 9.6K
17/05/24 Last post  Virgon Comments Created with Sketch.  27  Views Created with Sketch.  9.6K 
PAB 30/04/24 89 32K
30/04/24 Last post  salty74 Comments Created with Sketch.  89  Views Created with Sketch.  32K 
PAB
M & A Activities
02/04/24 1 596
02/04/24 Last post  Outgoing123 Comments Created with Sketch.  1  Views Created with Sketch.  596 
PAB 22/03/24 0 395
22/03/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  395 
PAB 22/03/24 0 292
22/03/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  292 
PAB 01/03/24 10 4.2K
01/03/24 Last post  salty74 Comments Created with Sketch.  10  Views Created with Sketch.  4.2K 
PAB
2024 An Eventful Year
2
29/02/24 61 23K
29/02/24 Last post  Lumpster Comments Created with Sketch.  61  Views Created with Sketch.  23K 

See All Discussions arrow Created with Sketch.

Timeline

Appendix 4C - Quarterly - 31 March 2024
30 Apr 09:20
 
Positive preclinical data for deoxymabs in vasculitis
09 Apr 09:31
 
Change of Director's Interest Notice
22 Mar 09:53
 
Notification of cessation of securities - PAB
22 Mar 09:48
 
Presentation to highlight broader potential of Deoxymabs
04 Mar 10:06
 
Appendix 4D - Half Year Accounts - 31 December 2023
23 Feb 14:51
 
View More arrow Created with Sketch.
(20min delay)
Last
0.8¢
Change
0.000(0.00%)
Mkt cap ! $16.46M
Open High Low Value Volume
0.8¢ 0.8¢ 0.8¢ $1.336K 167K

Buyers (Bids)

No. Vol. Price($)
22 8034700 0.7¢
 

Sellers (Offers)

Price($) Vol. No.
0.8¢ 1996944 7
View Market Depth
Last trade - 10.20am 24/05/2024 (20 minute delay) ?
PAB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.